Min Yang
Education
Ph.D. and M.S., health outcomes, The University of Texas at Austin College of Pharmacy; M.D., clinical medicine, Suzhou Medical College
Summary of Experience
Dr. Yang specializes in health economics and outcomes research (HEOR). She works closely with pharmaceutical, biotech, and device companies to develop HEOR strategies and to generate evidence throughout the product life cycle for value proposition. Dr. Yang designs and conducts studies from pipeline product development through product launch, post-market research, and biosimilar evaluation. She has extensive experience with clinical trial data, health insurance claims databases, electronic medical records, medical charts, primary surveys (including cross-sectional and prospective longitudinal cohort research), and qualitative research for evidence generation, with conventional and innovative methodologies.
Dr. Yang is an expert in clinical outcome assessments – such as patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs) – as well as health preference research. She has supported the development and validation of multiple PROs and ClinROs, generated evidence for regulatory submissions, and supported real-world evidence (RWE) strategies. A frequent collaborator with academic experts and clinical key opinion leaders, Dr. Yang’s research has been published in many peer-reviewed journals and presented at numerous clinical and economic research conferences. Dr. Yang is a licensed oncology surgeon in China and an adjunct assistant professor at The University of Texas at Austin College of Pharmacy. Prior to joining Analysis Group, she was a senior scientist at QualityMetric.
-
Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
Infectious Diseases and Therapy, 2024
2024Feuerstadt P, Allegretti JR, Dubberke ER, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke LL, LaPlante K, Garey KW, Khanna S
-
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study
Dermatology and Therapy, 2024
2024Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Truong B, Puig L, Lebwohl M
-
Assessing the Impact of Open-Label Designs in Patient-Reported Outcomes: Investigation in Oncology Clinical Trials
JNCI Cancer Spectrum, 2023
2023Lord-Bessen J, Signorovitch J, Yang M, Georgieva M, Roydhouse J
-
Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-Jslm [FMBL]) for Preventing Recurrent Clostridioides Difficile Infection in the US
Advances in Therapy, 2023
2023Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M
-
Burden of Hyperphagia and Obesity in Bardet-Biedl Syndrome: A Multicountry Survey
Orphanet Journal of Rare Diseases, 2023
2023Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM
-
Caregiver Burden in Bardet-Biedl Syndrome: Findings from the CARE-BBS Study
Orphanet Journal of Rare Diseases, 2023
2023Forsythe E, Mallya UG, Yang M, Huber C, Cala ML, Greatsinger A, Hagopian E, Pomeroy J, Haqq AM
-
Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-Jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides Difficile Infection in the USA
Advances in Therapy, 2023
2023Lodise T, Guo A, Yang M, Cook EE, Song W, Yang D, Wang Q, Zhao A, Bochan M
-
Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
Advances in Therapy, 2023
2023Reveles KR, Yang M, Garcia-Horton V, Edwards ML, Guo A, Lodise T, Bochan M, Tillotson G, Dubberke ER
-
Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study
Dermatology and Therapy, August 8, 2023
2023Kimball AB, Delevry D, Yang M, Chuang C, Wang Z, Bégo-Le-Bagousse G, Martins B, Wu EQ, Shumel B, Wang J, Sierka D, Chao J, Strober B
-
Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis
Advances in Therapy, 2023
2023Toro W, Yang M, Georgieva M, Song W, Patel A, Jiang AX, Zhao A, LaMarca N, Dabbous O
-
Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
Open Forum Infectious Diseases, 2023
2023Garey KW, Dubberke ER, Guo A, Harvey A, Yang M, García-Horton V, Fillbrunn M, Wang H, Tillotson GS, Bancke LL, Feuerstadt P
-
Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey
Advances in Therapy, 2023
2023Toro W, Yang M, Georgieva M, Anderson A, LaMarca N, Patel A, Akbarnejad H, Dabbous O
-
-
Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior
Advances in Therapy, 2022
2022Beisel C, Poretta T, Sheppard VB, Hurtado-de Mendoza A, Sipsma H, Fuqua E, Stwalley B, Salvatore A, Yang M
-
Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEURO-TTR trial
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Zhu JJ, Greatsinger A, Bozas A, Vera-Llonch M, Signorovitch J
-
Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen
Muscle & Nerve, 2022
2022Karam C, Brown D, Yang M, Done N, Dieye I, Bozas A, Vera-Llonch M, Signorovitch J
-
Patient Preferences for Attributes of Biologic Treatments in Moderate to Severe Asthma: A Discrete Choice Experiment Study
Patient Preference and Adherence, 2022
2022Yang M, Chao J, Fillbrunn M, Mallya UG, Wang MJ, Franke L, Cohn L, Kamat S
-
Treatment Outcomes Associated with Dupilumab Use in Patients with Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study
JAMA Dermatology, 2021
2021Strober B, Mallya UG, Yang M, Ganguli S, Gadkari A, Wang J, Sierka D, Delevry D, Kimball AB
-
The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis
Advances in Therapy, 2021
2021Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM
-
Impact of Medication Adherence on Healthcare Resource Utilization, Work Loss, and Associated Costs in a Privately Insured Employed Population Treated With Adalimumab in the United States
Journal of Occupational and Environmental Medicine, 2021
2021 -
Economic Benefit from Improvements in Health-Related Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Advances in Therapy, 2021
2021Bergman M, Tundia N, Yang M, Orvis E, Clewell J, Bensimon A
-
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy
Advances in Therapy, 2021
2021Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, Igarashi A
-
The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis
Journal of the American Academy of Dermatology, 2021
2021Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Bensimon A, Huang X, Joshi AD, Elewski B
-
Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis
European Urology Oncology, March 19, 2020
2020Kamat AM, Lerner SP, O’Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA
-
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
JAMA Dermatology, 2020
2020Augustin M, Lambert J, Zema C, Thompson EHZ, Yang M, Wu EQ, Garcia-Horton V, Geng Z, Valdes JM, Joshi A, Gordon KB
-
Short-term costs associated with non-medical switching in autoimmune conditions
Clinical and Experimental Rheumatology. 2019 Jan-Feb;37(1):97-105
2019Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A
-
Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections
Advances in Therapy, 2019
2019Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D
-
Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
BMC Dermatology, 2019
2019Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D
-
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review
Advances in Therapy, 2019
2019 -
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials
Value in Health. Jan 2018;21(1):1-8
2018Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE
-
Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States
Health and Quality of Life Outcomes. 2018 Sep 21;16(1):193
2018 -
Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa
Journal of the American Academy of Dermatology, June 2017, Volume 76, Issue 6
2017 -
Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk
American Journal of Epidemiology. 2017;186(6):736-744
2017Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjønneland A, Overvad K, Cai T, Jensen MK.
-
Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world
Clinical and Experimental Rheumatology. Sep-Oct 2017;35(5):791-798
2017Yang M, Galebach PJ, Signorovitch JE, Garg V
-
Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US
J Med Econ. 2015 Mar 27:1-10
2015Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.
-
Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two ph
Antimicrob Agents Chemother. 2015 Feb; 59(2):1119-26
2015Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM
-
Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease
Eur J Endocrinol. 2014 Jul; 171(1):89-98
2014Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M
-
Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
Br J Dermatol. 2014 Dec; 171(6):1434-42
2014Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M
-
A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy
Eur J Gastroenterol Hepatol. 2013 Jun; 25(6):739-47
2013Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J
-
Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain
Pain Med. 2012 Sep; 13(9):1110-20
2012Kavanagh S, Kwong WJ, Hammond GC, Nelson W, Upmalis D, Yang M
-
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine
Headache. 2012 Mar; 52(3):409-21
2012Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.
-
A qualitative study on feasibility of a web-based Women's Health Portal and Information System
Patient. 2011; 4(1):67-8
2011Yang M, Kosinski M, Boulanger R
-
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
Arthritis Res Ther. 2011 Feb 16; 13(1):R25
2011Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH.
-
Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine
Cephalalgia. 2011 Feb; 31(3):357-67
2011Yang M, Rendas-Baum R, Varon SF, Kosinski M.
-
Measuring the health status burden in hemodialysis patients using the SF-36® health survey
Qual Life Res. 2011 Apr; 20(3):383-9
2011Yarlas AS, White MK, Yang M, Saris-Baglama RN, Bech PG, Christensen T
-
A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients
Qual Life Res. 2010 Nov; 19(9):1349-58
2010Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.
-
Interpreting Premenstrual Symptoms Impact Survey scores using outcomes in health-related quality of life and sexual drive impact
J Reprod Med. 2010 Jan-Feb; 55(1-2):41-8
2010Yang M, Gricar JA, Maruish ME, Hagan MA, Kornstein SG, Wallenstein GV
-
Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder
Appl Health Econ Health Policy. 2010; 8(2):129-40
2010Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.
-
Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference
Curr Med Res Opin. 2009 Oct; 25(10): 2487-94
2009Yang M, Morin CM, Schaefer K, Wallenstein GV.
-
Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format
Curr Med Res Opin. 2009 Mar; 25(3):717-27
2009Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A
-
Antipsychotic medication utilization trends among Texas veterans: 1997-2002
Ann Pharmacother. 2008 Sep; 42(9):1229-38
2008Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J, Mascarenas CA.
-
Burden of premenstrual dysphoric disorder on health-related quality of life
J Womens Health (Larchmt). 2008 Jan-Feb; 17(1):113-21
2008Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S
-
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension
J Clin Hypertens (Greenwich). 2008 Jun; 10(6):436-42
2008Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S; TROPHY Study Investigators
-
Factors related to antipsychotic oversupply among Central Texas Veterans
Clin Ther. 2007 Jun; 29(6):1214-25
2007Yang M, Barner JC, Worchel J.
-
Mapping MOS Sleep Scale scores to SF-6D utility index
Curr Med Res Opin. 2007 Sep; 23(9):2269-82
2007Yang M, Dubois D, Kosinski M, Sun X, Gajria K.
-
Frequency of new-onset diabetes mellitus and use of antipsychotic drugs among Central Texas veterans
Pharmacotherapy. 2004 Nov; 24(11):1529-38
2004Barner JC, Worchel J, Yang M.
-
May 15, 2022
-
November 12, 2023
-
May 31, 2024
-
November 20, 2024
-
April 11, 2024
-
December 7, 2023
-
December 6, 2023
-
March 2, 2023
-
May 12, 2022
-
January 19, 2022
-
January 12, 2021
